Healthcare Providers
Healthcare providers must be certified in the CAMZYOS REMS in order to prescribe CAMZYOS.
A REMS is a strategy to manage known or potential serious risks associated with a drug. It is required by the US Food and Drug Administration (FDA) to ensure that the benefits of a drug outweigh its risks. Due to the risk of heart failure due to systolic dysfunction, CAMZYOS is only available through a restricted program called the CAMZYOS REMS.
The objectives of the CAMZYOS REMS are to:
CAMZYOS is a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.
Please see full Prescribing Information.
Cannot serve request to /content/commercial/us/camzyosrems/en/home/_jcr_content/root/experiencefragment_1827745916..html/bms-commercial/components/content/general/experiencefragment on this server